Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06190301

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

Led by Zhongshan Ophthalmic Center, Sun Yat-sen University · Updated on 2026-04-20

108

Participants Needed

1

Research Sites

314 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This project proposes to establish a prospective, multicenter, randomized, controlled clinical study to compare the safety and efficacy of Intralesional Rituximab Injection versus Involved Site Radiation Therapy for the treatment of primary ocular adnexal MALT lymphoma. The aim is to provide high-level clinical evidence for the treatment of ocular adnexal MALT lymphoma and to offer patients treatment options that have fewer complications and comparable therapeutic effects.

CONDITIONS

Official Title

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 to 75 years old
  • Diagnosed primary ocular adnexal MALT lymphoma based on pathology, clinical signs, and WHO classification
  • TNM staging T1-3 without involvement of intraconal compartment
  • Willing to participate and able to sign informed consent
Not Eligible

You will not qualify if you...

  • TNM staging T2/T3 with intraconal compartment involvement or stage T4
  • Previous local or systemic radiation, chemotherapy, or drug treatment for ocular adnexal MALT lymphoma
  • Presence of cataract requiring surgery soon or cataract affecting vision below 20/40
  • Need for other ocular surgeries besides lymphoma treatment
  • Other ocular diseases including corneal infections, iridocorneal endothelial syndrome, microphthalmos, uveitis, glaucoma, ocular trauma, retinal disorders
  • Presence of HBV or HIV infection
  • Requirement for long-term local or systemic steroid use
  • Participation in other drug clinical trials
  • Pregnant or breastfeeding women
  • Serious systemic diseases such as advanced cardiac, kidney, respiratory diseases, or other malignancies
  • Unable to understand the research content

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhongshan Ophthalmic Center, Sun Yat-Sen University

Guangzhou, Guangdong, China, 510060

Actively Recruiting

Loading map...

Research Team

R

Rong Lu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma | DecenTrialz